
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is a promising early-stage biotech company with a strong balance sheet and multiple shots on goal in the form of 13 active clinical trials. The company's primary focus on developing Ampligen for the treatment of late-stage pancreatic cancer is a smart decision, given the success of trials and the high mortality rates of the disease. Upcoming positive clinical data and progress on pivotal studies have the potential to be major catalysts for the stock. However, investors should be aware of the risks associated with biotech investments, including regulatory approval and commercialization challenges.
Bears say
AIM ImmunoTech is currently facing significant financial and regulatory risks which could hinder the future development and commercialization of its drug candidates. With a long development road ahead and uncertainties surrounding regulatory approvals and commercialization, the potential market for AIM's drugs may not fully materialize, making its stock a high-risk investment. Additionally, while the company has multiple clinical trials underway, its success is not guaranteed as there is intense competition in the biotech industry and changing macroeconomic factors may impact investor sentiment for investing in this sector.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares